PTC Therapeutics (PTCT) Set to Announce Quarterly Earnings on Thursday

by · The Cerbat Gem

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.52) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.16). The business had revenue of $186.70 million during the quarter, compared to analysts’ expectations of $192.12 million. On average, analysts expect PTC Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $40.87 on Wednesday. The business’s fifty day moving average price is $36.92 and its two-hundred day moving average price is $34.74. The company has a market capitalization of $3.14 billion, a P/E ratio of -6.48 and a beta of 0.63. PTC Therapeutics has a 1-year low of $18.15 and a 1-year high of $43.40.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PTCT shares. Robert W. Baird reaffirmed an “outperform” rating and set a $44.00 target price on shares of PTC Therapeutics in a research note on Tuesday, October 8th. Baird R W raised PTC Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Raymond James started coverage on PTC Therapeutics in a research report on Thursday, October 10th. They set a “market perform” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $64.00 price target on shares of PTC Therapeutics in a research report on Tuesday, September 17th. Finally, UBS Group started coverage on PTC Therapeutics in a research report on Monday, August 26th. They set a “buy” rating and a $47.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $40.08.

Check Out Our Latest Stock Analysis on PTCT

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

See Also